Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
All 12 treated children with NTKR, ROS1 or ALK gene abnormalities showed partial or compete tumor shrinkage.
There are now five targeted therapies for the most common type of liver cancer.
An ongoing study is assessing pediatric and young adult cancers that did not respond to initial treatments.
Only a small percentage of people who inject drugs and those with sexual risk factors received the cancer-preventing vaccine.
As smoking rates decline, the proportion of lung cancer cases that are among never smokers is increasing.
Leronlimab (PRO 140) also shows promise as a treatment for cancer and graft-versus-host disease.
Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.
Antibody-drug combination reduced the risk of recurrence after surgery by half compared with Herceptin.
Collaboration with Lazarex Cancer Foundation tests new ways to erase cost barriers in major public health issue.
The drug is still associated with a lower liver cancer rate than Baraclude.
Researchers have developed a new model that more accurately estimates HPV infection trends.
Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.
Curing the virus was associated with a lower risk of liver cancer recurrence.
Black women, as well as those with Medicaid or no insurance, were less likely to receive surgery and more likely to die.
The method identifies which targeted therapies, inadequate on their own, can be paired up to kill non-responsive cancers.
An early study conducted among those with indolent lymphoma showed promising results.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.